MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Apr 15, 2025.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 15, 2025

Income

$67,500.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.